Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?

Said, Medhat M; Broen, Martinus P G; Swart, Eleonora L; Bartelink, Imke H; Kouwenhoven, Mathilde C M.

Afiliação

Said MM; Department of Pharmacy & Clinical Pharmacology, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Broen MPG; Cancer Treatment and Quality of Life, Cancer Center Amsterdam, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
Swart EL; Department of Neurology, Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands.
Bartelink IH; GROW-School for Oncology and Reproduction, Maastricht University, 6229 ER Maastricht, The Netherlands.
Kouwenhoven MCM; Department of Pharmacy & Clinical Pharmacology, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

Cancers (Basel) ; 15(5)2023 Mar 02.

Article em En | MEDLINE | ID: mdl-36900352

Glioblastoma multiforme is the most common primary central nervous system tumor, with an incidence of 3 [...].

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article